| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/08/2000 | WO2000032168A1 Utilisation of capsules containing one or more antigenic substances for the prevention and/or treatment of autoimmune diseases |
| 06/08/2000 | WO2000015659A3 Stomach polypeptide zsig28 |
| 06/08/2000 | WO2000012481A3 Indazole derivatives with 5-ht2 receptor activity________________ |
| 06/08/2000 | WO2000011191A3 Tpl-2/cot kinase and methods of use |
| 06/08/2000 | WO2000009086A3 Protected one-vial formulation for nucleic acid molecules, methods of making the same by in-line mixing, and related products and methods |
| 06/08/2000 | WO2000004137A9 Human aspartic proteases |
| 06/08/2000 | WO1999033475A8 Galactosylceramide, glucosylceramide, lactosylceramide, and specific catchers therefor for use in the prophylaxis or therapy of prediabetes, diabetes and/or associated complications |
| 06/08/2000 | CA2385845A1 Methods of reducing serum glucose and triglyceride levels and for inhibiting angiogenesis using substituted indolealkanoic acids |
| 06/08/2000 | CA2353798A1 Controlled release formulation comprising gnrh-ii |
| 06/08/2000 | CA2353394A1 Benzamide derivatives and their use as apob-100 secretion inhibitors |
| 06/08/2000 | CA2353079A1 Gamma-ketoacid tetrapeptides as inhibitors of caspase-3 |
| 06/08/2000 | CA2352789A1 Use of selected modulators of p2 purinoceptors for the prevention of damage and mortality caused by global cerebral ischemia and ischemia-reperfusion |
| 06/08/2000 | CA2352487A1 Utilisation of capsules containing one or more antigenic substances for the prevention and/or treatment of autoimmune diseases |
| 06/08/2000 | CA2350597A1 Methods and compositions for restoring conformational stability of a protein of the p53 family |
| 06/08/2000 | CA2347701A1 .beta.-alanine derivatives as .alpha.4 integrin inhibitors |
| 06/08/2000 | CA2342621A1 8-azabicyclo[3.2.1]oct-2-ene and -octane derivatives |
| 06/07/2000 | EP1006115A2 Imidazopyridines having antihypertensive, cardioprotective, anti-ischemic and antilipolytic properties |
| 06/07/2000 | EP1005490A1 Zinc free insulin crystals for use in pulmonary compositions |
| 06/07/2000 | EP1005371A2 Method and food product for increasing muscle protein and reducing fat in animals |
| 06/07/2000 | EP1005327A1 Targeted liposomal constructs for diagnostic and therapeutic uses |
| 06/07/2000 | EP1005274A1 Orally active fraction of momordica charantia, active peptides thereof, and their use in the treatment of diabetes |
| 06/07/2000 | CN1255864A Combination of ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors |
| 06/07/2000 | CN1255829A Stable ascorbic acid inorganic salt liquid compsns., its prepn. method and applications |
| 06/07/2000 | CN1255501A Novel phosphonyl sulfonic ester compound and its medicinal compsns. |
| 06/07/2000 | CN1255371A Hypolipemic medicine for lossing weight and its preparing process |
| 06/07/2000 | CN1255369A Vital energy consolidating and weight lossing gruel |
| 06/07/2000 | CN1255358A Chinese medicine for treating diabetes |
| 06/07/2000 | CN1255349A Compound Chinese medicine for treating diabetes |
| 06/07/2000 | CN1255344A Typhlosis-resistant liquid for ophthalmopathy as complication of diabetes |
| 06/07/2000 | CN1053189C Pyridazino qujinoline compounds |
| 06/07/2000 | CN1053103C Pharmaceutical use of 24-homo-vitamin-D-derivative |
| 06/06/2000 | US6072068 Treating glucocorticoid-dependent diseases or symptoms |
| 06/06/2000 | US6072062 Synthesis of C18 -modified vitamin D compounds and compounds resulting therefrom |
| 06/06/2000 | US6071960 For treatment of diseases caused by or resulting in metabolic dysfunction and/or energy deprivation, such as diabetes, acute starvation, endotoxemia, sepsis, systemic inflammatory response syndrome and multiple orgen dysfunction syndrome |
| 06/06/2000 | US6071948 Treatment of diseases caused by excessive blood vessel growth |
| 06/06/2000 | US6071925 Antidepressants, anticonvulsants or antianxiety agents, also for treatment of memory loss in alzheimer's disease |
| 06/06/2000 | US6071919 Stimulate the immunological system and to induce the production of hypercellular bone marrow and extramedullary hematopoiesis; antitumor and -carcinogenic agents; autoimmune diseases; viricides; hepatitis |
| 06/06/2000 | US6071906 Inhibits or modulates the inducible isoform of nitric oxide synthase over the the constitutive isoforms; antiarthritic, -diabetic, ischemic, thrombosis agents; cardiovascular disorders; toxic shock syndrome; autoimmune diseases |
| 06/06/2000 | US6071899 Azetidinone derivatives for the treatment of atherosclerosis |
| 06/06/2000 | US6071885 Administering a cardiac glycosides and aglycone derivatives to inhibit export of leaderless proteins into extracellular spaces; useful in treatment of tumors and diabetes |
| 06/06/2000 | US6071747 Human preadipocytes for developing antiobesity and antidiabetic agents; cells include immortalizing fragment of viral oncogene, promoter from viral oncogene or human vimentin gene, and express certain proteins |
| 06/06/2000 | US6071722 Nucleic acids encoding a G-protein coupled 7TM receptor (AXOR-1) |
| 06/06/2000 | US6071697 Method for testing the differentiation status in pancreatic cells of a mammal |
| 06/06/2000 | US6071537 Administering cyclohexylmethanesulfamic acid or pyranyl-2-methanesulfamic acid derivatives |
| 06/06/2000 | US6071523 Oral administering from squeezable container; storage stability, heat resistance; drug delivery |
| 06/06/2000 | CA2198599C Salts of an anti-migraine indole derivative |
| 06/06/2000 | CA2114830C Lactone compound and process of production thereof |
| 06/04/2000 | CA2291471A1 Lowering blood levels of lipoprotein(a) |
| 06/02/2000 | WO2000031263A2 Gtpase associated proteins |
| 06/02/2000 | WO2000031137A1 Amino-terminal modified parathyroid hormone (pth) analogs |
| 06/02/2000 | WO2000031123A2 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof |
| 06/02/2000 | WO2000031120A2 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 06/02/2000 | WO2000031113A1 INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| 06/02/2000 | WO2000031084A1 Prostaglandin conjugates for treating or preventing bone disease |
| 06/02/2000 | WO2000031068A1 Polyhydroxylated heterocyclic derivatives as anti-coagulants |
| 06/02/2000 | WO2000031055A1 Chrystals of 5-[{6-(2-fluorobenzyl)oxy-2-naphthyl}methyl]-2,4-thiazolidinedione |
| 06/02/2000 | WO2000031047A1 Substituted 4-amino-2-aryl-cyclopenta[d]pyrimidines, their production and use and pharmaceuticalreparations containing same |
| 06/02/2000 | WO2000030665A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
| 06/02/2000 | WO2000030663A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases |
| 06/02/2000 | WO2000030657A1 A process for producing an iron-dextran compound |
| 06/02/2000 | WO2000030652A1 Use of dehydroepiandrosterone for increasing the number of nmda receptors in a mammal |
| 06/02/2000 | WO2000030624A2 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus |
| 06/02/2000 | WO2000030622A2 Utilisation of dialkylfumarates for treating host-versus-graft reactions and auto-immune diseases |
| 06/02/2000 | WO2000030477A1 Beverage for increasing the body's capacity to break down alcohol |
| 06/02/2000 | WO2000030425A2 Method of using pon-1 to decrease atheroma formation |
| 06/02/2000 | WO2000014236A3 Grf analogs with increased biological potency |
| 06/02/2000 | WO2000013650A3 Neuroprotection |
| 06/02/2000 | WO2000011030A3 Method for chromatographically purifying insulins |
| 06/02/2000 | WO1999066075A3 Diagnostic method based on quantification of extramitochondrial dna |
| 06/02/2000 | CA2352585A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of cardiovascular diseases |
| 06/02/2000 | CA2352510A1 Composition comprising soy protein, dietary fibres and a phytoestrogen compound and use thereof in the prevention and/or treatment of type 2 diabetes, the metabolic syndrome and associated cardiovascular diseases |
| 06/02/2000 | CA2352215A1 Beverage for increasing the body's alcohol degradation capacity |
| 06/02/2000 | CA2352154A1 Use of benzoylguanidines for the treatment of non-insulin-dependent diabetes mellitus |
| 06/02/2000 | CA2351980A1 Use of dehydroepiandrosterone for increasing the number of nmda receptors in a mammal |
| 06/02/2000 | CA2351679A1 Prostaglandin conjugates for treating or preventing bone disease |
| 06/02/2000 | CA2351361A1 Gtpase associated proteins |
| 06/02/2000 | CA2351354A1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis |
| 06/02/2000 | CA2350405A1 Method of using pon-1 to decrease atheroma formation |
| 06/02/2000 | CA2349290A1 Retro-inversion peptides that target gastro-intestinal tract transport receptors and use thereof |
| 06/02/2000 | CA2332882A1 A process for producing an iron-dextran compound |
| 05/31/2000 | EP1004594A1 Phytosterol and/or phytostanol derivatives |
| 05/31/2000 | EP1004582A2 Pyridazino quinoline compounds |
| 05/31/2000 | EP1004578A2 5-oxo-pyrrolidine-2-carboxylic acid hydroxamide derivatives |
| 05/31/2000 | EP1004306A2 Estrogen agonists/antagonists |
| 05/31/2000 | EP1004300A1 Anion regulator for ruminants |
| 05/31/2000 | EP1003862A1 Human longevity-assurance protein homologs |
| 05/31/2000 | EP1003783A2 Lipoprotein-regulating medicaments |
| 05/31/2000 | EP1003777A1 PGC-1, A NOVEL BROWN FAT PPAR$g(g) COACTIVATOR |
| 05/31/2000 | EP1003776A1 Gene and amino acid sequences for novel transcription factor |
| 05/31/2000 | EP1003772A1 Chemical modification of proteins to improve biocompatibility and bioactivity |
| 05/31/2000 | EP1003763A1 83 human secreted proteins |
| 05/31/2000 | EP1003761A2 A process for the purification of acarbose |
| 05/31/2000 | EP1003744A1 4-AMINOPYRROLE(3,2-d) PYRIMIDINES AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS |
| 05/31/2000 | EP1003737A1 Phenyl urea and phenyl thiourea derivatives as hfgan72 antagonists |
| 05/31/2000 | EP1003721A1 Benzylidene-1,3-dihydro-indol-2-one derivatives as receptor tyrosine kinase inhibitors, particularly of raf kinases |
| 05/31/2000 | EP1003532A1 Absorption of minerals by intestinal cells |
| 05/31/2000 | EP1003507A1 Combination therapy comprising amlodipine and a statin compound |
| 05/31/2000 | EP1003503A1 Therapeutic combinations comprising amlodipin and atorvastatin |
| 05/31/2000 | EP1003370A1 Method of enhancing magnesium absorption and prevention of atherosclerosis |
| 05/31/2000 | EP0865428B1 Vitamin d analogues |